Physician profile
Lara Farhat
NPI 1023352770
$3,934.36
in general payments reported to CMS, 2019-2025
25 companies · $1,529 in 2025
The $1,529 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $84.89 · 2021: $515 · 2022: $560 · 2023: $77.54 · 2024: $394 · 2025: $1,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,083.99 | 2019-2025 | |
| Abbvie INC. | $634.10 | 2022-2025 | |
| Optinose US, INC. | $356.64 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $245.39 | 2020-2025 | Dupixent, Libtayo |
| Glaxosmithkline, LLC. | $214.42 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Kaleo, INC. | $209.24 | 2020-2024 | Auvi-Q |
| Galderma Laboratories, L.P. | $200.71 | 2024-2025 | Nemluvio |
| Botanix Sb INC | $139.13 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $126.05 | 2022-2025 | |
| Incyte Corporation | $120.49 | 2021-2025 | Opzelura |
| Astrazeneca Pharmaceuticals LP | $102.23 | 2020-2025 | Tezspire |
| Shire North American Group INC | $73.45 | 2019 | |
| Amgen INC. | $68.47 | 2021-2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $55.84 | 2025 | Neffy |
| Lilly USA, LLC | $36.58 | 2025 | Ebglyss |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $36.56 | 2021-2022 | |
| Genentech USA, INC. | $36.05 | 2024 | Xolair |
| Biocryst US Sales Co., LLC | $35.15 | 2025 | Orladeyo |
| Leo Pharma INC. | $35.01 | 2025 | Anzupgo, Adbry |
| Pfizer INC. | $25.00 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $21.38 | 2021 | |
| Hikma Pharmaceuticals USA | $21.38 | 2021 | |
| Phadia US INC. | $19.54 | 2021 | |
| Sun Pharmaceutical Industries INC. | $19.25 | 2025 | |
| Blueprint Medicines Corporation | $18.31 | 2024 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lara Farhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.